Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.

Int J Cancer. 2019 Jul 4. doi: 10.1002/ijc.32551. [Epub ahead of print]

PMID:
31271443
2.

TRIM24 as an independent prognostic biomarker for prostate cancer.

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S.

Urol Oncol. 2019 Sep;37(9):576.e1-576.e10. doi: 10.1016/j.urolonc.2019.05.006. Epub 2019 Jun 7.

PMID:
31178279
3.

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.

Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.

4.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

5.

Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.

Luedeke M, Rinckleb AE, FitzGerald LM, Geybels MS, Schleutker J, Eeles RA, Teixeira MR, Cannon-Albright L, Ostrander EA, Weikert S, Herkommer K, Wahlfors T, Visakorpi T, Leinonen KA, Tammela TLJ, Cooper CS, Kote-Jarai Z, Edwards S, Goh CL, McCarthy F, Parker C, Flohr P, Paulo P, Jerónimo C, Henrique R, Krause H, Wach S, Lieb V, Rau TT, Vogel W, Kuefer R, Hofer MD, Perner S, Rubin MA, Agarwal AM, Easton DF, Al Olama AA, Benlloch S; PRACTICAL consortium, Hoegel J, Stanford JL, Maier C.

Hum Mol Genet. 2016 Dec 15;25(24):5490-5499. doi: 10.1093/hmg/ddw349.

6.

Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

Azoitei N, Kleger A, Schoo N, Thal DR, Brunner C, Pusapati GV, Filatova A, Genze F, Möller P, Acker T, Kuefer R, Van Lint J, Baust H, Adler G, Seufferlein T.

Neuro Oncol. 2011 Jul;13(7):710-24. doi: 10.1093/neuonc/nor084.

7.

Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.

Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F, Perner S.

Histopathology. 2011 Jun;58(7):1028-36. doi: 10.1111/j.1365-2559.2011.03862.x.

PMID:
21707704
8.

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.

Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM.

Nat Med. 2010 Jul;16(7):793-8. doi: 10.1038/nm.2166. Epub 2010 Jun 6.

9.

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.

Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S.

Mod Pathol. 2010 Aug;23(8):1061-7. doi: 10.1038/modpathol.2010.87. Epub 2010 May 14.

10.

ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA.

Urology. 2010 Apr;75(4):762-7. doi: 10.1016/j.urology.2009.10.010.

11.

POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma.

Kastler S, Honold L, Luedeke M, Kuefer R, Möller P, Hoegel J, Vogel W, Maier C, Assum G.

Prostate. 2010 May 1;70(6):666-74. doi: 10.1002/pros.21100.

PMID:
20017164
12.

Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.

Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5. doi: 10.1158/1055-9965.EPI-09-0772. Epub 2009 Oct 27.

13.

Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?

Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE.

J Urol. 2009 Dec;182(6):2632-7. doi: 10.1016/j.juro.2009.08.046.

PMID:
19836794
14.

RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M.

Neoplasia. 2009 Sep;11(9):956-63.

15.

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

Neoplasia. 2009 Aug;11(8):804-11.

16.

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.

Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM.

Cancer Res. 2009 May 15;69(10):4434-42. doi: 10.1158/0008-5472.CAN-08-3605. Epub 2009 Apr 14.

17.

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA.

Cancer Res. 2009 Apr 1;69(7):2734-8. doi: 10.1158/0008-5472.CAN-08-4926. Epub 2009 Mar 17.

18.

Oncological followup after radical cystectomy for bladder cancer-is there any benefit?

Volkmer BG, Kuefer R, Bartsch GC Jr, Gust K, Hautmann RE.

J Urol. 2009 Apr;181(4):1587-93; discussion 1593. doi: 10.1016/j.juro.2008.11.112. Epub 2009 Feb 23.

PMID:
19233433
19.

Distinct genomic aberrations associated with ERG rearranged prostate cancer.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA.

Genes Chromosomes Cancer. 2009 Apr;48(4):366-80. doi: 10.1002/gcc.20647.

20.

Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.

Cancer Res. 2009 Jan 15;69(2):640-6. doi: 10.1158/0008-5472.CAN-08-2008.

21.

Nosocomial bacteriuria in patients with indwelling catheter after radical retropubic prostatectomy for prostate cancer.

Bartsch GC, Kuefer R, Braun C, Simon J, Kleinschmidt K, Hautmann RE, Volkmer BG.

Urol Int. 2008;81(4):389-93. doi: 10.1159/000167834. Epub 2008 Dec 10.

PMID:
19077397
22.

Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.

Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, Kuefer R, Rubin MA, Fimmel CJ, Chinnaiyan AM.

Neoplasia. 2008 Nov;10(11):1285-94.

23.

[11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study.

Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, Wittbrodt M, Egghart G, Moeller P, Blumstein N, Reske S, Kuefer R.

Urol Int. 2008;81(2):191-7. doi: 10.1159/000144059. Epub 2008 Aug 29.

PMID:
18758218
24.

Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.

Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schürmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA; PRACTICAL Consortium, Eeles RA.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61. doi: 10.1158/1055-9965.EPI-08-0317. Erratum in: Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2901. Donovan, Jenny [added]; Hamdy, Freddie [added].

25.

Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma.

Bachmann N, Haeusler J, Luedeke M, Kuefer R, Perner S, Assum G, Paiss T, Hoegel J, Vogel W, Maier C.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):103-10. doi: 10.1016/j.cancergencyto.2008.01.006.

PMID:
18406871
26.

Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction.

Simon J, Kuefer R, Bartsch G Jr, Volkmer BG, Hautmann RE, Gottfried HW.

BJU Int. 2008 Aug;102(4):459-62. doi: 10.1111/j.1464-410X.2008.07560.x. Epub 2008 Mar 5.

27.

Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia.

Sträter J, Wiesmüller C, Perner S, Kuefer R, Möller P.

Histopathology. 2008 Feb;52(3):399-402. Epub 2007 Dec 13. No abstract available.

PMID:
18081815
28.

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE.

BJU Int. 2007 Oct;100(4):786-93.

29.

[Systemic therapy approaches in patients with bone metastases of urogenital malignancies].

Finter F, Mottaghy FM, Kuefer R, Hautmann RE, Rinnab L.

Urologe A. 2007 Aug;46(8):904, 906-12. Review. German.

PMID:
17639296
30.

Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.

Merseburger AS, Hennenlotter J, Stenzl A, Beger G, Rinnab L, Kuczyk MA, Kuefer R.

Urol Int. 2007;79(1):41-3.

PMID:
17627167
31.

Clinical value of transrectal ultrasound in the diagnosis of suspected neoplasia in the small pelvis.

Rinnab L, Gottfried HW, Schnöller T, Hautmann RE, Kuefer R.

Ultraschall Med. 2007 Apr;28(2):195-200.

PMID:
17516275
32.

Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases.

Banyard J, Bao L, Hofer MD, Zurakowski D, Spivey KA, Feldman AS, Hutchinson LM, Kuefer R, Rubin MA, Zetter BR.

Clin Cancer Res. 2007 May 1;13(9):2634-42.

33.

[Ureteral stricture after extracorporeal shock wave lithotripsy. Case report and overview of the spectrum of rare side effects of modern ESWL treatment].

Finter F, Rinnab L, Simon J, Volkmer B, Hautmann R, Kuefer R.

Urologe A. 2007 Jul;46(7):769-72. Review. German.

PMID:
17458533
34.

[TMPRSS2-ETS gene fusion in prostate cancer].

Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M.

Urologe A. 2007 Jul;46(7):754-60. Review. German.

PMID:
17458530
35.
36.

Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer.

Kuefer R, Genze F, Zugmaier W, Hautmann RE, Rinnab L, Gschwend JE, Angelmeier M, Estrada A, Buechele B.

Neoplasia. 2007 Mar;9(3):246-53.

37.

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.

Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA.

Hum Pathol. 2007 May;38(5):696-701. Epub 2007 Feb 22.

PMID:
17320151
38.

Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer.

Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA, Collins C.

Neoplasia. 2006 Dec;8(12):1083-9.

39.

Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.

Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML.

Cancer Res. 2006 Dec 15;66(24):11897-906.

40.

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.

Cancer Res. 2006 Sep 1;66(17):8337-41.

41.

Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series.

Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG.

Eur Urol. 2007 Mar;51(3):690-7; discussion 697-8. Epub 2006 Jul 28.

PMID:
16904815
42.

The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.

Bastide C, Kuefer R, Loeffler M, de Petriconi R, Gschwend J, Hautmann R.

Prostate Cancer Prostatic Dis. 2006;9(3):239-44. Epub 2006 Jul 11.

PMID:
16832384
43.

ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML.

Neoplasia. 2006 Apr;8(4):319-29.

44.

Prognostic factors in lymph node-positive prostate cancer.

Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA.

Urology. 2006 May;67(5):1016-21.

PMID:
16698361
45.

Defining aggressive prostate cancer using a 12-gene model.

Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin MA.

Neoplasia. 2006 Jan;8(1):59-68.

46.

[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].

Kuefer R, Autenrieth M, Herkommer K, Blum P, Merseburger A, Hofer M, Rinnab L, Gschwend J, Ringhoffer M.

Urologe A. 2006 Mar;45(3):328, 330-5. Review. German.

PMID:
16465522
47.

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.

Science. 2005 Oct 28;310(5748):644-8.

48.

Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival.

Volkmer BG, Kuefer R, Bartsch G Jr, Straub M, de Petriconi R, Gschwend JE, Hautmann RE.

Cancer. 2005 Dec 1;104(11):2384-91.

49.

Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer.

Bachmann N, Hoegel J, Haeusler J, Kuefer R, Herkommer K, Paiss T, Vogel W, Maier C.

Prostate. 2005 Nov 1;65(3):252-9.

PMID:
16015586
50.

Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.

Kuefer R, Hofer MD, Zorn CS, Engel O, Volkmer BG, Juarez-Brito MA, Eggel M, Gschwend JE, Rubin MA, Day ML.

Br J Cancer. 2005 Jun 6;92(11):2018-23.

Supplemental Content

Loading ...
Support Center